Key Takeaways
- Pharma drives the quarter, Crop drags the year: EBITDA margin jumped 410 bps YoY to 22.4% as Pharma EBIT grew 47% YoY, while Crop Protection faces flattish FY26 revenue and margins before a promised FY27 recovery.
- The pipeline is deep but back-end loaded: Two Pharma CDMO NCEs in Phase III, 8 Crop Protection CDMO projects, 8 Animal Health products validated, and a new high-potency chemistry lab all point to a FY27 inflection, not an FY26 one.
- High-potency chemistry is the next unlock: A new lab commissioning in H2 FY26 targets a market where over 50% of new NCEs require high-potency handling, a capability that could expand the company's addressable RFP pool by 30-40%.
- Crop Protection is a waiting game: Management expects flattish revenue and margins for FY26, with growth resuming only in FY27, as the sector works through Chinese competitive pricing and innovator strategic transitions.
- What to watch next quarter: Whether the high-potency lab stays on track for Q3 commissioning, any early revenue from the faster-moving Phase III molecule, and the pace of Animal Health commercial launches now that 8 products are validated.
Pharma: The Growth Engine
- API volume-led growth: The API business grew on higher volumes and increased offtake of new molecules, while the CDMO segment benefited from improved offtake from key innovator clients and building momentum.
- EBIT leverage in action: Pharma EBIT grew 47% YoY, driven by operating leverage, operational excellence, an expanded customer base and improved capacity utilization.
- FY26 growth anchored at 12-15%: Management expects approximately 12% to 15% revenue growth in FY26, with EBIT margins rising proportionately through operating leverage, and the same growth range extending into FY27 as the base business grows and lifecycle management molecules ramp up.
- Pipeline built for annual launches: The current pipeline holds 8 to 9 differentiated products, with plans to commercialize 2 to 3 launches each year.
- CDMO catalysts sit in 2026-27: Two NCE programs are progressing well in Phase III trials and are expected to transition to commercial scale in 2026-27, with one molecule moving faster and potentially contributing some revenue in FY26 before a good ramp-up in 2027.
- Geographic reach expanding: Marketing footprint is being built out in Japan, Latin America, Korea, the Middle East and Southeast Asia, supported by expanded business development teams and new global offices in North America, Japan and Europe set up in the last 6 to 12 months.
Hiremath: "The first ones are the hardest to win. I think we're overcoming that hurdle. And now the next ones will be much easier and will ramp up quite rapidly."
Crop Protection: Stabilization Before Growth
- Sector under structural pressure: Competitive pricing, especially from China, and strategic transitions across innovator companies are reshaping the Crop Protection landscape.
- FY26 outlook is flat: Management expects muted growth for FY26, with revenue and margins flattish, before growth resumes in FY27 and margins return to historical levels seen in FY22 and FY23.
- H2 FY26 may show early improvement: Some improvement is expected in the second half of FY26, though the full recovery waits until FY27.
- CDMO pipeline stays active: The Crop Protection CDMO vertical is managing a robust pipeline of 8 active projects with existing and new strategic customers, reflecting increasing trust in development and manufacturing capabilities for complex and on-patent molecules, with advanced-stage projects expected to launch from FY27 onwards.
- Specialty products gaining traction: The own-product vertical is seeing demand driven by customer appetite for innovation, high performance and sustainable solutions.
- High launch probability in agro: Agrochemical molecules carry a launch probability above 75% since registration and stock studies are already completed, a structural advantage over Pharma where attrition from Phase I to Phase III is higher.
Hiremath: "Based on the above strategic initiatives, although we expect muted growth in FY 2026, we expect growth to resume in FY 2027."
Animal Health & Specialty Chemicals: The Next Legs
- Animal Health validation milestone reached: Eight products have been validated for global supply under a long-term partnership with a leading innovator, and the company is now free to sell to any customer worldwide, though each customer must validate the product in their own formulation.
- Commercial launches approaching: Validation is scheduled to be completed in the upcoming quarter, supporting product registration and paving the way for commercial launches in the next several quarters across key global markets.
- New client NCE work encouraging: Early-stage outcomes with new clients for NCEs have been encouraging, and steady progress continues on developing multiple APIs for the lead innovator customer.
- Specialty Chemicals portfolio ready to launch: An established portfolio of several products will begin launching by the second half of FY26.
- Food ingredient project on track: The project remains on track and is expected to reach peak revenue within the next 2 to 3 years.
High-Potency Chemistry: The Next Capability Unlock
- Lab commissioning in H2 FY26: A new high-potency chemistry lab is being launched this year, with commissioning expected in Q3 and operations beginning by the end of FY26.
- Targeting a structural demand shift: Over 50% of new NCEs now require high-potency chemistry, and customers are increasingly confident about outsourcing this capability to India, a shift from just a couple of years ago.
- RFP participation set to expand: The company currently does not cater to high-potency RFPs; management expects the new capability to increase RFP participation by 30-40%, though it cautions that "only time will tell" how much converts.
Hiremath: "If you look at the new NCEs that are coming out, more than 50% of the new NCEs are now high potent chemistry."
Costs, Capex & Balance Sheet
- Employee cost optimization structural, not cyclical: Personnel costs were lowered through a detailed year-long exercise to repurpose people across plants and sites, combined with digitalization initiatives that improved plant efficiencies and productivity, and these benefits are expected to continue.
- Other expenses carried one-off items: Q4 other expenses rose by ₹10-12 crores due to additional repair and maintenance for customer audits, higher sales and year-end shipments, plus a provision for doubtful debts per accounting standards; audit-related charges and doubtful debt provisions are characterized as items that will keep changing.
- Interest cost driven by working capital: Higher working capital utilization in the middle period pushed absolute interest cost up, despite a 20-25 bps reduction in the interest rate.
- Capex plan steady at ~₹200 crores per year: Planned for both FY26 and FY27.
- ROE/ROCE to face Crop division drag: Pharma division returns will improve, but significant depreciation charges from a large asset capitalized in Q3 in the Crop division will pull consolidated ROE/ROCE down slightly or keep it flat next year.
- Peak profit still 2-3 years out: Management estimates it will take at least 2 to 3 years to get back to the peak PAT of approximately ₹160 crores.
- R&D spend consistent: The company is consistently allocating 4% to 5% of revenue toward R&D.
- FDA observations responded to: The company responded to all observations received in February, confirmed no data integrity issues, and is awaiting the FDA's response; management declined to comment further on the nature of the observations.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Pharma revenue growth | 12% to 15% growth, with EBIT margins rising proportionately through operating leverage | FY26 |
| Pharma growth consistency | 12% to 15% growth year-on-year | FY26 and FY27 |
| Crop Protection revenue and margins | Flattish | FY26 |
| Crop Protection growth resumption | Growth to resume, margins return to FY22/FY23 historical levels | FY27 |
| Crop Protection CDMO commercialization | Advanced-stage projects to launch | FY27 onwards |
| Specialty Chemicals launches | Portfolio to begin launching | H2 FY26 |
| Pharma CDMO commercial scale | Two NCE programs transition to commercial scale | 2026-27 |
| High-potency chemistry lab | Commissioned and operational | Q3 FY26 (operational by end FY26) |
| Animal Health commercial launches | Product registration and commercial launches across key global markets | Next several quarters |
| Food ingredient project peak revenue | Peak revenue achieved | Within 2 to 3 years |
| Capex | ~₹200 crores each year | FY26 and FY27 |
| Peak PAT recovery | Return to ~₹160 crores PAT | At least 2 to 3 years |
Key Metrics
| Metric | Q4 FY25 |
|---|---|
| Revenue | ₹552 cr, full year FY25 ₹1,860 cr |
| EBITDA | ₹123 cr, +71% QoQ and +31% YoY |
| EBITDA margin | 22.4%, improved 410 bps YoY |
| Full-year EBITDA margin | 17.7%, improved 270 bps YoY |
| Pharma revenue | ₹351 cr, full year FY25 ₹1,168 cr |
| Pharma EBIT | ₹55 cr, full year FY25 ₹137 cr, +47% YoY |
| Pharma EBIT margin improvement | 327 bps YoY |
| Crop Protection revenue | ₹201 cr, full year FY25 ₹692 cr |
| Crop Protection EBIT | ₹36 cr, full year FY25 ₹79 cr |
| Crop Protection EBIT margin | 18%, full year FY25 11.4% |
| Total dividend FY25 | ₹1.40 per share, 70% of face value |
| Pharma revenue growth guidance FY26 | 12% to 15% |
| Crop Protection growth outlook FY26 | Flattish revenue and margins; growth expected to resume in FY27 |
| Capex plan FY26 and FY27 | ~₹200 cr each year |
| ROE FY25 | 7.3% |
| ROCE FY25 | 9.9% |
| PAT FY25 | ₹91 cr, peak PAT was ~₹160 cr in FY22 |
| R&D allocation | 4% to 5% of revenue consistently |
| Pharma CDMO pipeline | 12 to 15 products in advanced stages of development or commercialization, up from 6 to 9 previously |
| Crop Protection CDMO active projects | 8 active projects |
| Animal Health products validated | 8 products validated under long-term agreement with innovator |
| Minimum project size target | $5 million, ideally $10 million; peak revenue per molecule target ₹50 cr to ₹200 cr+ |
| Agrochemical molecule launch success rate | More than 75% |